Table 4.
A. Summary measures* | |||
---|---|---|---|
BWH (N=1023) | EPIC (N=467) | Comparison | |
DRB1*1501 | 0.272 | 0.269 | 0.69 |
GRS95, mean | 5.1 | 5.1 | 0.86 |
B. Comparison of women and men** | |||||||||
---|---|---|---|---|---|---|---|---|---|
BWH | EPIC | Combined | |||||||
Women (N=776) | Men (N=247) | p-value | Women (N=318) | Men (N=149) | p-value | Women (N=1094) | Men (N=396) | p-value | |
DRB1*1501 | 0.283 | 0.239 | 0.0278 | 0.294 | 0.215 | 0.0149 | 0.286 | 0.23 | 0.0012 |
GRS95, mean | 5.09 | 5.13 | 0.193 | 5.08 | 5.14 | 0.0287 | 5.09 | 5.14 | 0.0229 |
C. Association with age at MS onset *** | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Women (N=1087) | Men (N=394) | Combined (N=1481) | ||||||||||
beta | SE | t-stat | p-value | beta | SE | t-stat | p-value | beta | SE | t-stat | p-value | |
DRB1*1501 | −1.64 | 0.464 | −3.54 | 0.000422 | −0.465 | 0.846 | −0.55 | 0.583 | −1.33 | 0.407 | −3.27 | 0.00108 |
GRS95, mean | −0.433 | 0.454 | −0.954 | 0.34 | −1.15 | 0.763 | −1.5 | 0.134 | −0.64 | 0.39 | −1.64 | 0.101 |
Wilcoxon Rank Test
Wilcoxon-rank test. For the pooled analysis (CLIMB+EPIC), we controlled for cohort.
Linear regressions additive model (treating SNPs as a continuous variable (0,1,2), controlling for cohort. For the pooled analysis (men + women), we controlled for sex and cohort. Abbreviations: SE = standard estimate; t-stat = t statistic